Celyad Oncology S.A.
OTC: CLYYF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Michel E. J. Lussier
- Employees
- 17
- Headquarters
- Mont-Saint-Guibert, Belgium
- IPO year
- 2014
- Market cap
- $11.2M
- Website
- https://www.celyad.com
Loading CLYYF…
Loading profile data…Frequently asked questions about CLYYF
What does Celyad Oncology S.A. (CLYYF) do?
Celyad Oncology SA is a clinical-stage biopharmaceutical entity dedicated to the discovery and advancement of chimeric antigen receptor T (CAR-T) cell therapies for cancer treatment. Its prominent clinical programs include CYAD-101, an allogeneic CAR-T candidate in a Phase 1b trial for metastatic colorectal cancer. Another significant asset is C...
Where does CLYYF trade?
Celyad Oncology S.A. (CLYYF) trades on the Other OTC.
What sector is CLYYF in?
Celyad Oncology S.A. (CLYYF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Celyad Oncology S.A.?
Michel E. J. Lussier is the chief executive officer of Celyad Oncology S.A. (CLYYF).
Where is Celyad Oncology S.A. headquartered?
Celyad Oncology S.A. is headquartered in Belgium.
Does CLYYF pay a dividend?
Celyad Oncology S.A. (CLYYF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CLYYF go public?
Celyad Oncology S.A. (CLYYF) completed its initial public offering in 2014.